Reference,Reference: DOI,Assay,Section,Pre-vaccine Infection,Vaccine,# Shots,Months,Host,Control,Control: NT50 Cmp,Control: NT50 GeoMean,Control: NT50 GSD,Variant,Variant: Pos,Variant: Mutations,# Results,Potency: NT50 Cmp,Potency: NT50 GeoMean,Potency: NT50 GSD,Fold Reduction: Cmp,Fold Reduction: Median
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 2,None,mRNA-1273,2,2-6m,Human,Wild Type (B.1),=,984.0,1.0,Delta/K417N,19,T19R + G142D + Δ156-157 + R158G + K417N + L452R + T478K + P681R + D950N,1,=,364.0,1.0,=,2.7
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 2,None,mRNA-1273,2,2-6m,Human,Wild Type (B.1),=,972.0,1.0,Delta/K417N,19,T19R + G142D + Δ156-157 + R158G + K417N + L452R + T478K + P681R + D950N,1,=,239.0,1.0,=,4.1
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 2,None,mRNA-1273,2,2-6m,Human,Wild Type (B.1),=,774.0,1.0,Delta/K417N,19,T19R + G142D + Δ156-157 + R158G + K417N + L452R + T478K + P681R + D950N,1,=,264.0,1.0,=,2.9
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 2,None,mRNA-1273,2,2-6m,Human,Wild Type (B.1),=,509.0,1.0,Delta/K417N,19,T19R + G142D + Δ156-157 + R158G + K417N + L452R + T478K + P681R + D950N,1,=,82.0,1.0,=,6.2
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 2,None,mRNA-1273,2,2-6m,Human,Wild Type (B.1),=,1038.0,1.0,Delta/K417N,19,T19R + G142D + Δ156-157 + R158G + K417N + L452R + T478K + P681R + D950N,1,=,312.0,1.0,=,3.3
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 2,None,mRNA-1273,2,2-6m,Human,Wild Type (B.1),=,990.0,1.0,Delta/K417N,19,T19R + G142D + Δ156-157 + R158G + K417N + L452R + T478K + P681R + D950N,1,=,213.0,1.0,=,4.6
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 2,None,mRNA-1273,2,2-6m,Human,Wild Type (B.1),=,537.0,1.0,Delta/K417N,19,T19R + G142D + Δ156-157 + R158G + K417N + L452R + T478K + P681R + D950N,1,=,160.0,1.0,=,3.4